






Debbie Eagles | Research Program Director ISWAVLD 21 June 2019













































	Purpose						
Method	Population freedom from infection	Individual animal freedom from infection prior to movement	Contribute to eradication policies	Confirmation of clinical cases	Prevalence of infection – surveillance	Immune status in individual animals or populations post- vaccination	
	Agent identification						
Virus isolation/ HAD test ¹	n/a	n/a	++	•••	**	n/a	
FAT	n/a	n/a	++	++	+	n/a	
ELISA for antigen detection	+	**	+	+	+	n/a	
Conventional PCR	++	**	++	**	**	n/a	
Real-time PCR	+++	••••	+++	+++	***	n/a	
	Detection of immune response						
ELISA	+++	+++	+++	+	+++	n/a	
IPT*	+++	+++	+++	+	+++	n/a	
IFAT*	+++	+++	+++	+	+++	n/a	
IBT*	++	++	++	+	++	n/a	
	••••		•	~ • •		18 B. 18 B.	
DIE							
Laboratory Diagnosti	cs and Networking	in Asia					





- Detection of partial gene fragments of the ASFV genome (*B646L* gene encoding p72)
- Rapid (5-6 hrs) and highly sensitive
- Frontline choice for outbreak investigations (peracute, acute infections) and routine diagnostics
- Can detect ASFV in absence of infectious particles or when at low levels
 - ->Degraded or treated specimens (eg pork products)
 - →Low/moderate virulence strains


Assay	Target	Format	OIE	Reference
Aguerro	VP72	Conventional	Y	Aguerro et al. 2003. J. Clin. Micro. 41:4431
King (OIE)	VP72	Realtime	Y	King et al. 2003. J. Virol. Methods, 107:53
UPL	VP72	Realtime	Y	Fernández-Pinero et al. 2013. Trans. Emerg. Di 60:48
USDA (Zsak)	VP72	Realtime	N	Zsak et al. 2005. J. Clin. Micro. 43: 112
McKillen	9GL	Realtime	N	McKillen et al. 2010. J. Virol Methods. 168:141
Tignon	VP72	Realtime	N	Tignon et al. 2011. J. Virol. Methods. 178:161
Haines*	VP72	Realtime	N	Haines et al. 2013. PLoS ONE. 8: e71019
Luo	VP72	Conventional	N	Luo et al. 2017. Arch. Virol. 162:191
Ingenasa	VP72	Realtime	N	Based on UPL; INgene q PPA
IDEXX	?	Realtime	N	RealPCR ASFV DNA Mix
ID.Vet	?	Realtime	N	ID Gene [®] African Swine Fever Duplex
Tetracore	VP72	Realtime	N	Based on USDA assay
Applied Biosystems	VP72	Realtime	N	VetMAX ASF kit
Indical	?	Realtime	N	Virotype® ASFV PCR


Comparisons of Diagnostic performance


Comparison of PCR tests using tissues from domestic pigs experimentallyinfected with genotype I and II viruses (AAHL, unpublished)


		Mean Ct*					
Tissue type	Genotype	King (OIE)	Zsak (USDA)	McKillen	Ingenasa		
Lymph node	I	26.1	25.1	26.5	31.5		
Spleen	II	20.0	18.7	20.1	24.9		
Spleen	I	25.2	24.0	25.4	30.3		
Lung	II	22.2	20.3	22.1	26.8		
Liver	II	19.7	18.7	19.9	24.9		
Uninfected spleen	NA	Undetected	Undetected	Undetected	Undetected		
Spleen	II	19.8	19.3	20.5	25.3		
Lung	I	28.9	27.5	29.4	35.1		
Spleen	II	25.7	23.6	26.1	30.8		
Spleen	I	29.1	28.2	29.6	35.1		


King, Zsak and McKillen assays used AgPath-ID one-step RT-PCR reagents




















NIAH/AAHL OIE Laboratory Twinning Situation at Commencement Activity Summary Virus Isolation and conventional Good existing technical expertise. Cell lines provided and specific test (VIT and IFX) training provided through NIAH staff visits Situation at Completion for target diseases Ines especially for ASF Conventional to AAHL Cell lines provided and specific test (VIT and IFX) training provided through NIAH staff visits Expanded cell lines and established confirmatory immuno-tests including for ASF and PED. Priority Area Situation at Completion immuno-tests including Good comprehensive range of NIAH participates annually in FAO Ongoing high levels of test performance primers/probes reviewed and updated where required supported and AAHL managed Regional PT rounds for avian and PCR capabilities. achieved under the Regional PT rounds for swine diseases, which objectively measure their performance. NIAH uses the PT results to alert them to when corrective actions under their Quality system may be required. Review Serology Tests NIAH is now developing new tests NIAH has the expertise to develop or A comprehensive range of commercial ELISA tests existed. or improving some ELISA tests as e of serology test The PED serology tests were reviewed and comparative testing (ELISA, CFT, IFA and MAT for Lepto) and part of applied research projects for their staff. Training on test to undertake test comparisons and test validation analyses to determine test conducted with AAHL validation techniques for new or improved tests was conducted. performance parameters including

Training of IFA for ASF was conducted

diagnostic sensitivity/specificity and repeatability

Standard Laboratory Diagnostics and Networking in Asia



16